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Abstract
b-galactoside a2, 6-sialyltransferse gene (ST6GAL) family has two members, which encode corresponding enzymes ST6Gal I
and ST6Gal II. The present atudy was to investigate whether and how ST6GAL family involved in multidrug resistance (MDR)
in human leukemia cell lines and bone marrow mononuclear cells (BMMC) of leukemia patients. Real-time PCR showed a
high expression level of ST6GAL1 gene in both MDR cells and BMMCs (*P,0.05). Alternation of ST6GAL1 levels had a
significant impact on drug-resistant phenotype changing of K562 and K562/ADR cells both in vitro and in vivo. However, no
significant changes were observed of ST6GAL2 gene. Further data revealed that manipulation of ST6GAL1 modulated the
activity of phosphoinositide 3 kinase (PI3K)/Akt signaling and consequently regulated the expression of P-glycoprotein (P-
gp, *P,0.05) and multidrug resistance related protein 1 (MRP1, *P,0.05), which are both known to be associated with MDR.
Therefore we postulate that ST6GAL1 is responsible for the development of MDR in human leukemia cells probably through
medicating the activity of PI3K/Akt signaling and the expression of P-gp and MRP1.
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Introduction
MDR and disease relapse are often regarded as the causes of the
failure of chemotherapeutic drug treatments in patients diagnosed
with malignant neoplasm including leukemia [1]. Numerous
reports have focused on the mechanisms of MDR of tumor cells,
for example the expression of drug transporting pumps, changes in
the targets of anticancer drugs, decrease of drug activity, as well as
changes in apoptosis regulatory pathways that contribute to MDR
[2–4]. MDR is conventionally regarded as the consequence of
overexpression of transporter proteins belonging to the ATP
binding cassette (ABC) family such as P-gp and MRP1, which lead
to lower intracellular drug accumulation and hence reduce cellular
toxicity of chemotherapeutic agents [5]. Recently, researchers pay
more attention to the relationship between glycan alterations and
resistance to chemotherapy of neoplastic cells. Although structure
modifications of glycans have been observed in drug-resistance
leukemia cells, little is known about the effects of glycosyltrans-
ferases or relevant glycogenes on the development of leukemia
drug-resistance [6,7].
Sialic acids, which are terminal monosaccharide attached to
glycan chains of cell surface, are commonly found in glycocon-
jugates. Various sialic acid decorations on the cell surface are
shown to be involved in many biological processes, such as cell
recognition, cell adhesion, receptor activation, cancer progression,
metastatic spread and signal transduction [8–9]. ST6GalI is a
sialyltransferase that links the sialic acid residues to terminal
galactose of glycan chains by a- 2, 6-linkage [10]. It distributes
widespread tissue-specific distribution in mammals, and the
aberrant expression of ST6GalI is often related to poor prognoses
in colon, epithelial tumors, gastric cancers and acute myeloid
leukemia [6,11–13]. Overexpression of ST6GalI was involved in
chemotherapy resistance in ovarian tumor cells [14]. The altered
levels of ST6GalI were also found in Hca-F and Hca-P murine
hepatocarcinoma cells with differed invasive properties both in vitro
and in vivo [15]. In contrast to ST6GalI, ST6GalII, a recently
identified additional sialyltransferase, confines to human intestine,
colon and brain [16,17]. It exhibits relatively low and no activities
toward some glycoproteins and glycolipids respectively and seems
to recognize oligosaccharides to glycoproteins as acceptor
substrates [18,19]. Tremendous studies have focused on the
involvement of sialylation in tumorigenesis, but the relationship
between ST6GalI or ST6GalII and MDR remains unclear.
PI3K/Akt signaling activation might be implicated in the
progression of a wide variety of neoplasias [20]. Recent research
illustrated that aberrant activation of PI3K/Akt pathway contrib-
uted to the survival and drug resistance of different types of human
neoplasm cells [21,22]. Activation of Akt was associated with poor
prognosis and chemotherapeutic resistance in pediatric B-precur-
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sor acute lymphoblastic leukemia [23]. In leukemic cells,
chemoresistance was shown to be maintained by PI3K/Akt
signaling activation, and could be reversed by LY294002, a known
PI3K/Akt antagonist [24]. PI3K/Akt kinase pathway also
modulated P-gp-mediated multidrug resistance in L1210/VCR
mouse leukemic cell line [25]. But Tazzari showed that that in
human acute myelogenous Leukemia (AML) blasts a strong
correlation exists between upregulation of the PI3K/Akt survival
pathway and MRP1 expression, whereas such a relationship was
not found for the P-gp [26]. However, little is known regarding the
effect of the signaling pathways on ST6GalI, ST6GalII-mediated
leukemia MDR.
The aims of the present study were to determine sialylated
oligosaccharide alterations and the expression level of ST6GAL
family among the four pairs of parental and chemoresistant
human leukemia cell lines. In addition, we examined the
regulation of ST6Gal I or ST6Gal II in leukemia MDR via
PI3K/Akt pathway and the possible mechanisms.
Results
Differential expression of ST6GAL1, ST6GAL2 in four pairs
of leukemia cell lines
To analyze the expression profiles of ST6GAL family in drug
sensitive and MDR cells, a real-time RT-PCR analysis was
performed. ST6GAL1 was significantly expressed at an elevated
level in four MDR cell lines compared with those of four drug-
sensitive parental cell lines. By contrast, no significant change of
ST6GAL2 was observed. Western blotting analysis further
confirmed the enzyme expression in drug sensitive and MDR
cells at protein level. These data indicated that differential
ST6GAL1 expression might be associated with MDR of leukemia,
as illustrated in Fig. 1A and B.
Suppression of ST6GAL1 gene enhances
chemosensitivity of K562/ADR cells in vitro and in vivo
Due to the significant increase of ST6GAL1 mRNA and protein
expression in K562/ADR cells, we silenced, by shRNA,
ST6GAL1 to elucidate the direct implication of ST6GAL1 in
the chemosensitivity of K562/ADR cells. As shown in Fig. 2A and
B, the expression of ST6GAL1 was significantly reduced in K562/
ADR-shRNA transfectants compared with control transfectants
both at transcription and protein level. K562/ADR-shRNA-1
transfectant was chosen for the following experiments.
After ST6GAL1 shRNA transfection, the ability of adriamycin,
paclitaxel and vincristine to inhibit the growth of K562/ADR was
evaluated by MTT assay. The results showed that IC50 values
were significantly decreased in K562/ADR-ST6GAL1 shRNA
group compared to the control, suggesting that cell proliferation
was inhibited by therapeutic drug and chemosensitivity was
remarkably restored when ST6GAL1 gene was suppressed
(Fig. 2C).
To investigate how knockdown of ST6Gal1 gene impacted on
chemosensitivity of leukemia cells, we used nude mice bearing
K562/ADR and K562/ADR-ST6GAL1 shRNA-1 xenografts to
analyze the differences of tumor volumes when therapeutic drugs
were administrated. A significant reduction of mean tumor volume
of K562/ADR-ST6GAL1 shRNA-1 tumor was observed, as
compared with K562/ADR-control shRNA (Fig. 2D). After the
measurement of tumor volume, tumors were sectioned for IHC
staining analysis of ST6GalI expression pattern, the expression of
it was reduced in the mice group with shRNA treatment compared
to untreated group or control group (Fig. 2E).
In addition, a-2, 6 sialylation level at the cell surface, detected
by FITC-conjugated SNA, was also decreased by treatment with
shRNA in K562/ADR cells (Fig. 2F).
Overexpression of ST6GAL1 gene mediates MDR in K562
cells in vitro and in vivo
To explore the effect of ST6GAL1 on chemosensitivity, a K562
cell line stably expressing ST6GAL1 was established. It was found
that the levels of ST6GAL1 mRNA, protein and a2, 6-linked sialic
acid were increased notably in ST6GAL1 transfectants
(Fig. 3A.B.F). The IC50 values for the drugs were significantly
increased in the K562/ST6GAL1 group than those in the K562/
mock group. Thus, the overexpression of ST6GAL1 in K562 cells
resulted in decreased chemosensitivity to antitumor drugs in vitro
(Fig. 3C).
Nude mice were inoculated with tumor cells K562, K562/mock
and K562/ST6GAL1. Tumor volumes were measured and
compared between the groups with or without adriamycin
treatment. Fig. 3D showed that in the group of mice bearing
K562 tumors, tumor volumes with adriamycin treatment were
lower than those without. But in the group of mice bearing K562/
ST6GAL1 tumors, tumor volumes increased significantly even
after adriamycin treatment. High expression level of ST6GalI in
tumor cells of K562/ST6GAL1 was also validated by IHC
staining, as shown in Fig. 3E. Thus, overexpression of ST6GAL1
gene in K562 cells led to raised resistance to chemotherapy.
Effect of ST6GAL1-activated PI3K/Akt signaling pathway
on the expression of P-gp and MRP1 expression
It has been reported that the PI3K/Akt signaling pathway is
activated in K562 cell line [27]. Here, we assessed the activity of
the PI3K/Akt signaling by ST6GAL1 shRNA-1 treatment in
K562/ADR cells. Western blotting (Fig. 4A) showed that the levels
of P110a (the catalytic subunit of PI3K), phosphorylation of Akt at
Ser473 and Thr308, and NF-kB were significantly reduced with
shRNA transfection. However, there was no change in the total
amount of Akt protein. Conversely, over-expression of ST6GAL1
in K562 cells enhanced proteins expression of P110a, Akt Ser473,
Akt Thr308, and NF-kB, as illustrated in Fig. 4B.
P-gp and MRP1 are the recognized molecules which contrib-
uted to the development of MDR [5]. Hence, we investigated
whether ST6GAL1 could influence the expression of P-gp and
MRP1. Interestingly, flow-cytometric analysis (Fig. 4C and 4D)
illustrated that elevated expression levels of P-gp and MRP1 were
detected in K562/ST6GAL1 cells compared to those of control
cell groups. In addition, K562/ADR cells expressed lower levels of
P-gp and MRP1 with ST6GAL1 supression. Therefore, the data
might indicate an additional mechanism of ST6GAL1 in MDR of
leukemia cells.
Inhibition of PI3K/Akt pathway increases the
chemosensitivity of K562/ADR cells both in vitro and in
vivo
In order to explore the activity of PI3K/Akt signaling pathway
on chemoresistance of K562/ADR cells, PI3K/Akt pathway was
pharmacologically inhibited. As seen in Fig. 5A, K562/ADR cells
with LY294002 treatment or Akt siRNA showed obviously
decreased protein levels of the main signal molecules of PI3K/
Akt pathway. By MTT assay in vitro, we observed the inhibition of
PI3K/Akt pathway sensitized K562/ADR cells to chemotherapy
(Fig. 5B), the similar results were also observed by in vivo
chemosensitivity analysis, reduced tumor volumes were detected
in mice group bearing K562/ADR tumors with impaired PI3K/
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Akt signaling (Fig. 5C). Altered expression levels of the main signal
molecules of PI3K/Akt pathway in mice group bearing K562/
ADR tumors with LY294002 or Akt siRNA treatment were also
validated by IHC staining, as shown in Fig. 5D
Moreover, to investigate whether suppression of PI3K/Akt
signaling activity could influence the expression of P-gp and
MRP1, a flow-cytometric analysis was carried out. Lower levels of
P-gp and MRP1 were present in K562/ADR cells with LY294002
or Akt siRNA treatment (Fig. 5E). The results implicated a role for
PI3K/Akt signaling in regulating P-gp and MRP1 expression and
modulating the chemoresistance of K562/ADR cells.
Overexpression of ST6GAL1 is detected in patients’ AML
and CML cases with chemoresistance
Expression of MDR-related marker, ST6GAL1 and ST6GAL2
in leukemia patients is summarized in Table 1. The frequency of
P-gp positivity was 92.1% (70 of 76) in AML patients and 86.2%
(25 of 29) in CML patients. Then patients were divided into four
groups: AML without MDR, AML/MDR, CML without MDR
and CML/MDR. As was shown in Table 2, there was a significant
difference in the expression of ST6GAL1 between AML/MDR
patients (91.4%, 64 of 70) and those without MDR (16.6%, 1 of 6).
Accordingly, the proportion of ST6GAL1 positive CML/MDR
samples was 90.9% (20 of 22), this was found to be significantly
higher than the chemosensitive CML group (28.5%, 2 of 7).
However, expression of ST6GAL2 showed no difference between
drug resistant groups and chemosensitive groups. According to
these results, it was further confirmed the role of ST6GAL1 over-
expressions in drug resistance of leukemia cells.
Discussion
Clinically chemotherapy resistance is the result of interaction of
numerous biological variables [28]. MDR, as an issue with
increasing concern, contributes to the chemotherapy failure in
leukemia. Recently, some progresses have been gained in revealing
the mechanism of MDR [29]. Our study continued to investigate
the role of ST6GalI in mediating MDR in human leukemia cells
and its possible mechanisms.
Aberrant expression of sialylated glycans has been detected in
carcinomas of pancreas, gastric, breast, bladder, brain and colon
[30–34]. In this study, we found the expression profiles of
ST6GAL1 in four pairs of human leukemia cell lines and in the
tumor cells of leukemia patients by using a real-time PCR analysis.
All the leukemia cells with MDR were characterized with higher
expression levels of ST6GAL1 compared to the cells without
MDR. ST6GAL1 is known to be involved in the process of
proliferation, invasion, and apoptosis of cancer cells [35,36]. From
our results we postulate that abnormal expression of ST6GAL1
also involves in the development of MDR possibly, another
malignant behavior of tumor cells. There was not a significant
difference of ST6GAL2 expression between the cell groups with or
without MDR.
Figure 1. Differential expression of ST6GAL1 and ST6GAL2 in four pairs of leukemia cell lines. (A) The mRNA levels of ST6GAL1 and
ST6GAL2 analyzed by real-time PCR. Four ADR cells expressed higher levels of ST6GAL1 mRNA than their parental cell types (*P,0.05). No significant
changes of ST6GAL2 were observed. (B) Western blotting analysis of ST6GalI and ST6GalII at protein levels. GAPDH served as a control. Data are the
means 6 SD of triplicate determinants.
doi:10.1371/journal.pone.0085113.g001
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As up-stream regulators of glycoproteins, glycosyltransferases
catalyzed the biosynthesis of glycans. They often exhibit abnormal
activity in tumors and participate in the process of drug-resistance
development [37]. Zhang et al have observed an elevated level of
ST6GAL1 in drug resistance cell line K562/ADR [7]. However, a
comprehensive understanding of how ST6GAL1 correlated with
the MDR of human leukemia cells was not currently available. In
this study, we targeted ST6GAL1, which was over-expressed in
K562/ADR cells, and altered the expression levels of the
glycogene. A link was found between differential expression levels
of ST6GAL1 and changed drug-resistant phenotypes of K562 and
K562/ADR cells both in vitro and in vivo (Fig. 2, 3). Thus, based
Figure 2. Silence of ST6GAL1 gene enhances the chemosensitivity of K562/ADR cell both in vitro and in vivo. (A) ST6GAL1 transcript
was decreased apparently in K562/ADR cells by shRNA treatment. (B) After shRNA transfection, distinct reduction of ST6Gal 1 was observed at protein
levels by western blotting analysis. (C) Cell chemosensitivity was assessed by cytotoxicity assays. The reported values are the IC50 (Mean 6 SD) of
three independent experiments. IC50 represents the drug concentration producing 50% decrease of cell growth. *P,0.05 vs K562/ADR-control shRNA
cells. (D) When exposed to adriamycin, the tumor volume of nude mice bearing K562/ADR-ST6GAL1 shRNA-1 xenograft was significantly diminished
(*P,0.05). (E) Down-regulation of ST6GAL1 was also shown by IHC staining in xenograft tumors derived from K562/ADR-ST6GAL1 shRNA-1 cells
(4006). (F) Flow cytometry analysis showed a lower expression of ST6GAL1 in K562/ADR cells with ST6GAL1 transfection. The data are means 6 SD of
3 independent assays (*P,0.05).
doi:10.1371/journal.pone.0085113.g002
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on this insight we hypothesized that ST6GAL1 might function as a
critical factor involved in MDR.
The PI3K/Akt signal transduction pathway plays a pivotal role
in controlling neoplastic cell growth, survival, motility, invasion
and drug resistance [38–40]. Recent data has confirmed the
correlation of the ST6GAL1-mediated PI3K/Akt signaling
pathway with multidrug resistance [36,40]. Increasing evidences
showed that PI3K/Akt signaling was frequently activated in AML
cell lines and patient blasts and strongly contributed to prolifer-
ation, survival, and drug resistance of these cells [41–45]. Akt1
activity/phosphorylation was also up-regulated in MDR human
T-lymphoblastic leukemic CEM cells [46]. Here, we demonstrated
that the K562/ADR cell line presented higher PI3K/Akt activity
than the sensitive one, which was in accordance with the MDR
phenotype. Altered expression of ST6GAL1 remarkably modu-
lated the activity of PI3K/Akt pathway in human leukemia cell
Figure 3. Overexpression of ST6GAL1 gene enhances the chemoresistance of K562 cells both in vitro and in vivo. After transfection,
ST6GAL1 mRNA (A) and protein (B) were increased notably in K562 cells by real time PCR and western blot. (C) Cell chemosensitivity was assessed by
cytotoxicity assays. The reported values are the IC50 (Mean 6 SD) of three independent experiments. IC50 represents the drug concentration
producing 50% decrease of cell growth. *P,0.05 vs K562/mock cells. (D) An increase of mean tumor in mice group with K562/ST6GAL1 was observed,
as compared with that in K562 group and K562/mock group. Within K562/ST6GAL1 group, an increase of tumor growth was found in group without
ADR, compared with that with ADR (*P,0.05). (E) Up-regulation of ST6GAL1 was also shown by IHC staining in xenograft tumors derived from K562/
ST6GAL1 cells (4006). (F) Increased expression of ST6GAL1 was detected by flow cytometry analysis in K562/ST6GAL1 cells. The data are means 6 SD
of 3 independent assays (*P,0.05).
doi:10.1371/journal.pone.0085113.g003
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lines. Furthermore, blockage of PI3K/Akt pathway by Akt-specific
inhibitor, LY294002, or Akt siRNA reversed ADR cells to
chemosensitivity, indicating that ST6GAL1 might promote the
development of MDR probably through activating the PI3K/Akt
signaling pathway (Fig. 5). Thus, consistent with already reported
results, LY294002 can antagonize P-gp-mediated multidrug
resistance [25].
It has been reported that the PI3K/Akt signaling enhances drug
efflux by ATP-binding cassette (ABC) transporters in order to
maintain MDR of tumor cells [47]. ABC transporters are a
superfamily of transmembrane proteins that transports a wide
variety of substrates across cell membranes. They are found on the
surface of normal cells and various cancer cells, where they play
significant roles in the development of MDR [48]. As two main
members of ABC transporters, P-gp and MRP1 are frequently
Figure 4. Effect of ST6GAL1-activated PI3K/Akt signaling pathway on the expression of P-gp and MRP1. (A) The main molecules of
PI3K/Akt pathway were repressed at protein levels with ST6GAL1 shRNA transfection in K562/ADR cells. (B) The increased protein levels of PI3K/Akt
signaling molecules were determined by western blot in K562/ST6GAL1 cells. (C) Decreased expression of P-gp and MRP1 were examined by flow
cytometry analysis in K562/ADR-ST6GAL1 shRNA cells. (D) Flow cytometry analysis revealed a higher co-expression of P-gp and MRP1 in K562 cells
with ST6GAL1 transfection. The data are means 6 SD of 3 independent assays (*P,0.05).
doi:10.1371/journal.pone.0085113.g004
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Figure 5. PI3K/Akt inhibition changes the chemosensitivity of K562/ADR cells both in vitro and in vivo. (A) The K562/ADR cells were
pretreated LY294002 or Akt siRNA. Expressions of PI3K/Akt signaling molecules were then examined by western blot analysis. LY294002 or Akt siRNA
treatment also alleviated chemoresistance of K562/ADR cells, revealed by in vitro (B) and in vivo (C). (D) Down-regulation of PI3K/Akt signaling
molecules was also shown by IHC staining in xenograft tumors derived from LY294002 or Akt siRNA treatment cells (4006). (E) Flow cytometry
analysis showed that inhibition of PI3K/Akt pathway resulted in reduced levels of P-gp and MRP1. The data are means 6 SD of 3 independent assays.
*P,0.05 vs DMSO treatment cells; #P,0.05 vs control siRNA treatment cells.
doi:10.1371/journal.pone.0085113.g005
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used as markers to screen MDR patients clinically. MRP1
expression is also under the control of the PI3K/Akt signal
transduction network in human acute myelogenous leukemia
blasts [26]. We found a positive relationship between the levels of
P-gp and MRP1 and the expression level of ST6GAL1, as well as
the activity of PI3K/Akt signaling in K562 and K562/ADR cell
lines. Since ST6GAL1 was observed as regulatory gene on the
activity of PI3K/Akt signaling, we assumed that ST6GAL1 might
increase the expression of P-gp and MRP1 through PI3K/Akt
pathway, thereby mediating MDR of leukemia cells.
In summary, our results demonstrate an association between
differential expression of ST6GAL1 and changed MDR pheno-
types of leukemia cells. The possible mechanism is ST6GAL1
activating the PI3K/Akt signaling pathway that results in the
expression of P-gp and MRP1. However, drug resistance is
multifactorial event, and multiple glycomic alterations could also
be responsible for these phenotypes. Therefore, the molecular
machanism of tumor MDR remains to be further investigated.
Materials and Methods
Cells
Four human leukemia cell lines, including a chronic myelog-
enous leukemia cell line (K562), an acute myelogenous leukemia
cell line (HL60), an acute promyelocytic leukaemia cell line (NB4),
and a leukemic monocytic cell line (U937) were obtained from the
KeyGEN Company (China). All cell lines were cultured in RPMI
1640 medium (Gibco, Grand Island, NY, USA) supplemented
with 10% heat inactivated fetal bovine serum (Gibco) and 1%
penicillin-streptomycin (Gibco) at 37uC in a humidified atmo-
sphere containing 5% CO2. Adriamycin (Sigma) was added to
parental cell cultures in stepwise increasing concentrations from
0.1 mg/ml to 5 mg/ml for 2 months to develop an adriamycin-
resistant (ADR) subline, namely K562/ADR, HL60/ADR, NB4/
ADR and U937/ADR, correspondingly. To maintain the MDR
phenotype, the complete medium of the resistant cell clones were
supplemented with 1.0 mg/L adriamycin. ADR cells were
maintained in complete medium without adriamycin for one
week and cells with .90% viability prior to subsequent
treatments.
Samples from leukemia patients
The study cohort was made up of 105 previously untreated
leukemia patients, including 76 cases of acute myeloid leukemia
(AML) and 29 cases of chronic myeloid leukemia (CML). All
patients were obtained in the First Affiliated Hospital of Dalian
Medical University between April 2010 and July 2012, and they
provided written informed consent, and the institutional ethics
committees of the First Affiliated Hospital of Dalian Medical
University approved the study as well as contents of the written
consent. The leukemic subtypes of AML were determined
according to the French-American-British classification as follows:
35, 27 and 14 cases of M2, M3 and M5, respectively. Patients’
clinical characteristics were given in Table 1. The diagnosis of
AML and CML was based on cytomorphology, cytochemistry,
multiparameter flow cytometry, immunology, molecular genetics
and cytogenetics.
Separation of leukemic blast cell
BMMC were separated by Ficoll-Hypaque density gradient
centrifugation from bone marrow or peripheral blood taken at the
initial diagnosis and were cultured in plastic dishes to remove
Table 1. Clinicopathologic characteristics of the leukemia patients.
Patients Demographics Subcategory AML(n = 76) CML(n = 29)
M2 M3 M5
Gender Male 24 19 10 19
Female 11 8 4 10
Age(years) Median 42 44 38 53
Range 15–79 18–70 12–70 17–76
Splenic enlargement 25 18 10 21
Hemoglobin,110.0 g/L 34 25 12 28
WBC count (109/L) 20–100 19 17 7 2
.100 2 0 1 27
Platelet count (109/L) ,300 32 26 14 20
.300 3 1 0 9
P-gp (+) 33 24 13 25
MRP1 (+) 31 23 12 26
ST6GAL1(+) 30 22 13 22
ST6GAL2(+) 6 5 3 4
doi:10.1371/journal.pone.0085113.t001
Table 2. The differential expression of ST6GAL1 and ST6GAL2
between MDR and chemosensitive patients.
AML(n = 76) CML(n = 29)
Group MDR Chemosensitivity MDR Chemosensitivity
70 6 22 7
ST6GAL1(+) 64 (91.4%)* 1 (16.6%) 20 (90.9%)* 2 (28.5%)
ST6GAL2(+) 13 (18.6%) 1 (16.6%) 3 (13.6%) 1 (14.3%)
*P,0.05 vs. patients without MDR.
doi:10.1371/journal.pone.0085113.t002
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adherent cells at 37uC for 24 h. Freshly separated non-adherent
cells were maintained in modified Dulbecco’s medium containing
10% fetal bovine serum, 10 mM b-mercaptoethanol, 2 mM L-
glutamine, 50 ng/mL human stem cell factor, 10 ng/mL human
interleukin-3, and 10 ng/mL human interleukin-6. The expres-
sions of P-gp and MRP1 were measured by flow cytometric assays
to determine the resistant phenotype of patients. ST6GAL1 and
ST6GAL2 levels of all patients were determined by real time PCR.
Real Time PCR analysis
Total RNA was isolated with Trizol reagents (Gibco BRL,
Rockville, MD, USA) and cDNA was synthesized using Quanti-
Tect Reverse Transcription Kit (QIAGEN, valencia, CA)
according to the manufacturer’s protocol. Real time PCR was
carried out on a Roche LightCycler480 real time PCR system
(Applied Biosystems, Foster City, CA) using QuantiTect SYBR
Green PCR Kit (QIAGEN, valencia, CA). After a denaturation
and polymerase activation step (15 min at 95uC), 40 cycles of
denaturation (15 s at 94uC), annealing (30 s at 58uC) and
extension (30 s at 72uC) were run. The sequences of the primers
used for the real-time PCR assays were as follows: 59-
CTTGTTTTCCTGCTCAGA-39 and 59-GCAAACAGAA-
GAAAGACCA- 39 for ST6GAL1, 59-ACGCTGCTGATT-
GACTCTTCT-39 and 59-CACATACTGGCA CTCATCTAA-
39 for ST6GAL2; 59-CTCCTCCACCTTTGACG-39 and 59-
CACCACC CTGTTGCTGTA-39 for GAPDH, the expression of






Total cell protein were electrophoresed in 10% SDS-PAGE gel
and blotted onto a polyvinylidene difluoride membrane. After
being blocked with 5% powdered skim milk for 2 h in phosphate-
buffered saline containing 0.1% Tween 20 (PBST), the mem-
branes were incubated with antibody (1:500 diluted, Abcam,
Cambridge, UK), overnight at 4uC, and then incubated with
secondary antibody anti-rabbit/mouse-HRP (1:2000 diluted,
Santa Cruz Biotech, Santa Cruz, CA). GAPDH antibody (1:200
diluted, Santa Cruz Biotech, Santa Cruz, CA) was used as a
control. All bands were detected using ECL Western blotting kit
(Amersham Biosciences, UK), according to the manufacturer’s
instruction.
Deregulation of ST6GAL1 in K562/ADR cells by RNAi
K562/ADR cells were transferred to a 6 well plate which was
seeded 56105 cells in 1 ml of growth medium in each well and
incubated at 37uC in a CO2 incubator. The cell cultures were
transfected with ST6GAL1 shRNA-1, ST6GAL1 shRNA-2 and
ST6GAL1 shRNA-3 (Thermo Fisher, Inc, 178042). Scrambled
shRNA was used as the negative control. ST6GAL1 shRNAs were
mixed with LipofectamineTM 2000 (Invitrogen). Transfer cells
were cultured and incubated at 37uC for 6 h, followed by
incubation with complete medium for additional 24 h. Then cells
were harvested for further study. The cell transfection efficiency
was 85% by fluorescent microscope and the cell viability was 90%
by trypan blue dye exclusion assay.
Over-expression of ST6GAL1 in K562 cells
The human ST6GAL1 coding region were obtained from
TaKaRa company (Dalian, China) and were inserted into the
pEGFP-N1 vector (Invitrogen, Carlsbad, CA) respectively using
EcoRI, XhoI sites. Cells were transfected with 5 mg of target gene
expression vector or empty vector (EV) in 100-mm dishes using
TurboFect Transfection Reagent (QIAGEN, valencia, CA)
according to the manufacturer’s instruction. After 60 days of
screening, the cell lines stably expressing ST6GAL1 (K562/
ST6GAL1), and empty vector (K562/mock) were established.
Then cells were collected for further explorations.
In vitro drug cytotoxic assay
MTT assay was used to measure the drug resistance. 16104
cells per well were plated in 96-well plate and incubated with
different anticancer drugs paclitaxel, vincristine, and adriamycin
(Sigma, St. Louis, MO) for 48 h, respectively. Then cells were
treated with 100 ml MTT (0.5 mg/ml, Sigma). After 4 h
incubation at 37uC in 5% CO2, 100 ml DMSO (Gibco) was
pipetted to solubilize the formazan product for 30 min at room
temperature. The spectrometric absorbance was measured at
490 nm by microplate reader (Model 680; Bio-Rad, Hercules,
CA). Each test was repeated three times. The drug resistance was
estimated by comparing the IC50 values (drug concentration that
inhibits cell growth by 50%) from growth inhibition curves.
In vivo chemosensitivity assay
Five-week-old nude mice were obtained from Animal Facility of
Dalian Medical University and were provided with sterilized food
and water. Approximately, 16107 K562 and 16107 K562/ADR
viable cells were injected subcutaneously into the right flank of
each nude mouse. When mice bearing palpable tumors (about 1
week after tumor cell inoculation), K562, K562/ST6GAL1,
K562/mock, K562/ADR, K562/ADR-control shRNA, K562/
ADR-ST6GAL1 shRNA-1 tumor-bearing mice were randomly
divided into control and treatment groups (n = 6 animals per
group). The treatment groups received 7 mg/kg adriamycin i.p.
three times a week for 3 weeks, and the control groups received
physiological saline alone. Mice were sacrificed and their tumors
were isolated, weighed, and photographed. The tumor volume was
calculated by the following formula: Tumor volume = 1/
2(length6width2). Experiments were approved by the Committee
on the Ethics of Animal Experiments of the Dalian Medical
University, China (Permit Number: 12-896).
Immunohistochemical (IHC) staining analysis
Visible tumors were removed from the mice and immunohis-
tochemistry was performed on paraffin embedded sections. The
slides were dried, deparaffinized, rehydrated. After deparaffiniza-
tion and blocking of endogenous peroxidase, the slides were
labeled overnight at 4uC with antibodies (Abcam, Cambridge,
UK) at a dilution of 1:200. The following staining was performed
at room temperature for 60 min with secondary streptavidin-
HRP-conjugated antibody (Santa Cruz Biotech, Santa Cruz, CA).
Finally, the sections were counterstained with hematoxylin and
cover-slipped. The Image-Pro Plus4.5 Software (Media Cybernet-
ics, USA) was used to analyze the expression of proteins.
Inhibition of the PI3K/Akt signaling
LY294002 (Sigma) or Akt siRNA was used to suppress the
activity of the PI3K/Akt signaling in K562/ADR cells. Briefly,
cells (16104 cells per well) were incubated with dimethyl sulfoxide
(DMSO), the PI3K inhibitor LY294002 (10 mM) dissolved in
DMSO, Akt control siRNA and Akt siRNA. Cells were collected
after 24 h. Changes in chemosensitivity and gene expression were
measured by MTT assay and western blot analysis, respectively.
Each experiment was run in triplicate to determine means and
SDs.
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Flow cytometry analysis
Tumor cells were washed with 16phosphate buffered saline
(PBS) buffer containing 20 g/L bovine serum, and then were
preincubated with 5% powdered skim milk for 30 min to block
nonspecific binding. For surface staining of P-gp and MRP1,
aliquots of cells were incubated with fluorescein isothiocyanate
(FITC)-anti human P-gp, MRP1 (Abcam, Cambridge, UK) or an
isotype control antibody (Santa Cruz Biotech, Santa Cruz, CA) for
40 min at 4uC at the recommended dilutions. For detection of a-2,
6 sialylation, cell lysates were incubated with FITC-Sambucus
nigra (SNA) lectin (Vector Laboratories, Inc). After repeated
centrifugation at 1000 r/min, labeled cells were resuspended in
0.2 ml PBS and were analyzed with FACSCalibur (BD Biosci-
ences, San Jose, CA, USA). Fluorescence intensity was measured
by Cell Quest software.
Statistical analysis
SPSS17.0 software was used, and each assay was performed at
least three times. The data were expressed as mean6SD and
Student’s t-test was used to determine the significance of
differences in multiple comparisons. *P,0.05 was considered to
be statistically significant.
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